H. West

发表

Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.

N. Senzer, J. Nemunaitis, M. Cheever, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.

Edward S. Kim, H. Groen, E. Smit, 2017 .

Comparison of outcomes for patients with lepidic pulmonary adenocarcinoma defined by 2 staging systems: A North American experience.

C. Wilshire, R. Aye, A. Farivar, 2016, The Journal of thoracic and cardiovascular surgery.

Bronchioloalveolar carcinoma: not as easy as "BAC".

D. Garfield, H. West, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

O-186 Computer-assisted image analysis of response of bronchioloalveolar carcinoma to ZD1839

D. Gandara, A. Seibert, J. Crowley, 2003 .

Bronchioloalveolar Carcinoma: The Case for Two Diseases comprehensive review

D. Garfield, H. West, J. Cadranel, 2008 .

Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma

G. Giaccone, M. Kris, G. Scagliotti, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.

J. Crowley, R. Livingston, D. Gandara, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer vaccines for the treatment and prevention of non small-cell lung cancer.

K. Schiffman, M. Disis, H. West, 2000, Clinical lung cancer.

Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126.

J. Crowley, D. Gandara, W. Franklin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

F. Hirsch, P. Bunn, D. Gandara, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance therapy in non-small-cell lung cancer

T. Stinchcombe, H. West, 2009, The Lancet.

Bronchioloalveolar carcinoma: the case for two diseases.

D. Garfield, H. West, J. Cadranel, 2008, Clinical lung cancer.

Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal.

F. Hirsch, P. Bunn, D. Gandara, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.

J. Crowley, D. Gandara, W. Franklin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126)

F. Hirsch, P. Bunn, D. Gandara, 2005 .

Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126).

J. Crowley, F. Hirsch, D. Gandara, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

F. Cappuzzo, A. Gazdar, F. Hirsch, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study

R. Herbst, D. Prager, I. Dimery, 2005 .

Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC

R. Herbst, J. Heymach, D. Prager, 2005 .

P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical

Edward S. Kim, H. Groen, T. Clackson, 2017 .

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

M. Socinski, A. Shaw, S. Ou, 2016, The Lancet. Oncology.

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Edward S. Kim, H. Groen, E. Smit, 2022, JTO clinical and research reports.

Myalgias and arthralgias associated with paclitaxel.

H. Linden, R. Livingston, J. Gralow, 2003, Oncology.

O-187 ZD1839 (iressa) in advanced bronchioloalveolar carcinoma (BAC): A preliminary report of SWOG SO126

D. Gandara, W. Franklin, K. Chansky, 2003 .

Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non–Small Cell Lung Cancer (NSCLC)

R. Salgia, A. Amini, M. Villalona-Calero, 2022, American journal of clinical oncology.

A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).

M. Socinski, A. Shaw, S. Ou, 2015 .

Mutational analysis of K-RAS and EGFR implicates K-RAS as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib

Helen X. Chen, F. Hirsch, D. Gandara, 2005 .

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Edward S. Kim, H. Groen, E. Smit, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Ruey-min Lee, S. Ou, Gregory Riely, 2014, The Lancet. Oncology.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

W. Guo, M. Socinski, Kwok-Kin Wong, 2013, Clinical Cancer Research.

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer

M. Socinski, A. Shaw, Gregory Riely, 2015, The Lancet. Oncology.

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.

J. Neal, Gregory Riely, D. Costa, 2021, Cancer discovery.

Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non–Small‐cell Lung Cancer: SWOG S0635 and S0636 Trials

F. Hirsch, K. Kelly, A. Wozniak, 2018, Clinical lung cancer.

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.

N. Reinmuth, F. Cappuzzo, T. Mekhail, 2019, The Lancet. Oncology.

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC

R. Salgia, A. Amini, M. Villalona-Calero, 2022, Cancers.

Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cance

Mari Mino-Kenudson, Natasha Rekhtman, M. Somerfield, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically De fi ned Advanced Non – Small Cell Lung Cancer

M. Socinski, Kwok-Kin Wong, L. Sequist, 2013 .

The Association between Polluted Neighborhoods and TP53-Mutated Non–Small Cell Lung Cancer

R. Kittles, S. Neuhausen, R. Salgia, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Edward S. Kim, H. Groen, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bronchioloalveolar Carcinoma

F. Hirsch, D. Gandara, W. Franklin, 2004, Clinical Cancer Research.

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.

Edward S. Kim, H. Groen, E. Smit, 2018 .

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

M. Socinski, S. Ou, A. Shaw, 2018, ESMO Open.

Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.

C. Obasaju, H. Wakelee, M. Perry, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).

Edward S. Kim, H. Groen, E. Smit, 2016 .

Management of Multifocal Bronchioloalveolar Carcinoma (BAC)

H. West, 2014 .